Trade Names:Amicar- Tablets 500 mg- Syrup 250 mg/mL
Trade Names:Aminocaproic Acid- Injection 250 mg/mL
Inhibits fibrinolysis to stop bleeding.
Zero order process; absorption rate of 5.2 g/h. C max is about 164 mcg/mL; T max is about 1.2 h.
Vd is about 23.1 L.IV
Vd is about 30 L.
Metabolite is adipic acid.
Renally eliminated. 65% is recovered in the urine as unchanged drug and 11% as the metabolite adipic acid. Renal clearance is 116 mL/min and total body clearance is 169 mL/min. T 1/2 is about 2 h.
3 h for single IV dose.
Treatment of excessive bleeding from systemic hyperfibrinolysis and urinary fibrinolysis.
Prevention of recurrence of subarachnoid hemorrhage; management of amegakaryocytic thrombocytopenia; abortion; or prevention of attacks of hereditary angioneurotic edema.
Active intravascular clotting; DIC; administration to newborns.
IV/PO 4 to 5 g in first hour; then 1 to 1.25 g/h for 8 h or until bleeding is controlled. Dosage over 30 g/24 h is not recommended.
Store in tightly closed container at room temperature.
May lead to increase in clotting factors, producing state of hypercoagulation.
Serum potassium level may be elevated, especially in impaired renal function.
Bradycardia; hypotension; peripheral ischemia; thrombosis.
Dizziness; headache; delirium; hallucinations; confusion; intracranial hypertension; stroke; syncope.
Tinnitus; decreased vision; watery eyes.
Nausea; diarrhea; abdominal pain; vomiting.
Increased BUN; renal failure.
Agranulocytosis; coagulation disorder; leukopenia; thrombocytopenia.
Dyspnea; nasal congestion; pulmonary embolism.
Injection site reaction; pain and necrosis; myalgia; myositis; myopathy (characterized by muscle weakness, fatigue, elevated creatinine phosphokinase, rhabdomyolysis associated with myoglobinuria and renal failure); edema; allergic and anaphylactic reactions; anaphylaxis; malaise.
Category C .
Safety and efficacy not established.
Not used in treatment of hematuria of upper UT origin unless possible benefits outweigh risks.
Hypotension, severe acute renal failure.
Copyright © 2009 Wolters Kluwer Health.